Investors Investors

Stock Quote

Stock Quote

3:58 PM EDT on Apr 23

Press Releases

Press Releases

All Releases
Apr 02, 2018

NEW YORK , April 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the H.C.

Mar 22, 2018
NEW YORK , March 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that the Company has received notification from the U.S.
Mar 20, 2018
NEW YORK , March 20, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the 17th
Mar 19, 2018
Significant correlation between overall tumor biomarker response and achievement of the primary and secondary endpoints in pivotal study of AZEDRA NEW YORK , March 19, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and
Mar 08, 2018
Company Preparing for Potential Commercial Launch of AZEDRA® (iobenguane I 131) Ahead of U.S. Food and Drug Administration ( FDA ) April 30th Action Date Enrollment Complete in Phase 3 Trial for PSMA-Targeted SPECT/CT Imaging Agent 1404; Top-Line Results Anticipated in Q3’18 Enrollment Ongoing in
Mar 01, 2018
NEW YORK , March 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that it will host a conference call and webcast to review the fourth
Feb 15, 2018
NEW YORK , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the 2018
Feb 05, 2018
NEW YORK , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that Patrick Fabbio , Chief Financial Officer, will present at the 2018 BIO
Feb 01, 2018
NEW YORK , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that data from the Company’s open-label pivotal Phase 2b study of AZEDRA ®
Jan 02, 2018
Top-line Data Expected in 3Q2018 NEW YORK , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that it has completed enrollment in its
Dec 29, 2017
NEW YORK , Dec. 29, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the U.S. Food and Drug Administration ( FDA ) has accepted for review
Nov 02, 2017
NDA (New Drug Application) for AZEDRA ® (iobenguane I 131) Submitted to the U.S. Food and Drug Administration ( FDA ) on October 31 st Positive Results from the Pivotal Phase 2b Study of AZEDRA Highlighted at Multiple Medical Conferences Clinical Trials for Prostate Cancer Product Candidates
Nov 02, 2017
NEW YORK , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it has completed the rolling submission of its New Drug Application
Oct 31, 2017
NEW YORK , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that management will present at two upcoming investor conferences in
Oct 23, 2017
NEW YORK , Oct. 23, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. , (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it will host a conference call and webcast to review the third
Oct 16, 2017
NEW YORK , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that data from several of the Company’s development programs will be
Oct 04, 2017
NEW YORK , Oct. 04, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that results from the Company’s Phase 2b study of AZEDRA ® , a
Sep 20, 2017
NEW YORK , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the Cantor Fitzgerald
Aug 31, 2017

Study results show that treatment with AZEDRA produced clinically meaningful and durable responses across multiple study endpoints, including radiographic tumor response, tumor biomarker response, and overall survival

Aug 31, 2017
- All Sections of New Drug Application (NDA) Have Been Submitted to the FDA, Except Notification of Pre-Approval Inspection Readiness - -Manufacturer Has Requested Additional Time to Prepare for  Pre-Approval Inspection of the Manufacturing Site - NEW YORK, NY, Aug.